NCT05205226

Brief Summary

This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
636

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 2, 2018

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 5, 2021

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 2, 2022

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

January 11, 2022

Completed
14 days until next milestone

First Posted

Study publicly available on registry

January 25, 2022

Completed
Last Updated

January 25, 2022

Status Verified

January 1, 2018

Enrollment Period

3.4 years

First QC Date

January 11, 2022

Last Update Submit

January 11, 2022

Conditions

Non Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

  • PFS

    Progression free survival time

    January 2018 to June 2021

Secondary Outcomes (1)

  • RT

    January 2018 to June 2021

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with non driver mutation advanced non-small-cell lung cancer non driver mutation

You may qualify if:

  • ≥18，Advanced Non-small Cell Lung Cancer Confirmed by Histopathology Patients received platinum-based chemotherapy combined with immunotherapy

You may not qualify if:

  • EGFR/ALK/ROS1 driver gene mutation
  • Chemotherapy only
  • Concurrent radio-chemotherapy
  • Surgery
  • Single-agent immunotherapy
  • No treatment information available

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hunan Cancer Hospital

Changsha, Hunan, 410013, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

tissue sample and plasma DNA

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Yongchang C Zhang, MD

    Hunan Cancer Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Head of Medical Oncology, Principal Investigator, Clinical Professor

Study Record Dates

First Submitted

January 11, 2022

First Posted

January 25, 2022

Study Start

January 2, 2018

Primary Completion

June 5, 2021

Study Completion

January 2, 2022

Last Updated

January 25, 2022

Record last verified: 2018-01

Locations

CN(1)